Recent Reports

Evidence report on acute migraine treatmentsThis report will serve as the basis for discussion during a public meeting on January 23, 2020.

View More on this Topic

ICER’s final report on JAK inhibitors for rheumatoid arthritis, including a summary of the public meeting and key policy recommendations.

View More on this Topic



ICER’s final assessment and report.

NOTE: After initial publication of the Unsupported Price Increase Report, Genentech provided ICER with exact values for the net price of Rituxan in Q42016 and Q42018, and the volume sold in 2017 and 2018. Due to the discrepancy between the exact values and the data ICER obtained from SSR Health, LLC, ICER decided to update the report with the data provided by Genentech.

 

View More on this Topic

Materials

CTAF

RA Update: Final Policy Recommendations

New England CEPAC

Hemophilia A Update: Open Input Period

New England CEPAC

Diabetes: Final Policy Recommendations

New England CEPAC

Beta Thalassemia: Stakeholder List

New England CEPAC

Beta Thalassemia: Draft Scoping Document

New England CEPAC

Beta Thalassemia: Open Input Period

ICER

Valuing A Cure Report: Final White Paper and Methods Adaptations

ICER

Valuing a Cure: ICER Responses to Public Comment

New England CEPAC

Diabetes: Response to Public Comments

ICER

Unsupported Price Increase Report

CVD: Final Policy Recommendations

Midwest CEPAC

NASH: Revised Scoping Document